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1. INTRODUCTION {#epi412295-sec-0001}
===============

Epilepsy is one of the common chronic neurologic diseases observed in all age groups from childhood to old age. The Rochester Study in the United States reported that the incidence of epilepsy was higher in infants and the elderly than in other generations,[1](#epi412295-bib-0001){ref-type="ref"} and that the prevalence of epilepsy increased with aging.[2](#epi412295-bib-0002){ref-type="ref"} Because the proportion of the elderly aged ≥65 years in Japan (25% in 2013) is predicted to increase rapidly (30% in 2025 and 40% in 2060),[3](#epi412295-bib-0003){ref-type="ref"} the number of patients with epilepsy may also increase in the future. Therefore, a prevalence study for adult epilepsy is needed to estimate the clinical and social burden of the disease. However, only one population‐based study has estimated the prevalence of adult epilepsy in Japan,[4](#epi412295-bib-0004){ref-type="ref"} and no studies in Japan have examined the prevalence and the causes of epilepsy separately in the middle‐aged and elderly. The purpose of the present study was to investigate these issues in a general Japanese adult population.

2. METHODS {#epi412295-sec-0002}
==========

The present cross‐sectional study was performed as a substudy of the Hisayama Study, a prospective cohort study of cardiovascular disease in a general Japanese population.[5](#epi412295-bib-0005){ref-type="ref"} The town of Hisayama is located in a suburb of the Fukuoka metropolitan area in Japan. The age, occupational distributions, and nutritional intake levels of the residents of Hisayama are similar to those of Japan as a whole.[5](#epi412295-bib-0005){ref-type="ref"} A comprehensive health examination for cardiovascular risk factors and epilepsy was performed in this town from June 2012 to November 2013. A total of 4679 residents aged ≥40 years were invited to participate in the examination by letters, telephone, or face‐to‐face invitations. The examination was performed mainly at the municipal center for health promotion in Hisayama. However, some subjects who could not visit the center due to disability, dementia, or severe diseases were interviewed in their homes, hospitals, or nursing homes so as to include as many participants as possible. Thus a final subject group of 3396 subjects participated in the health examination. After excluding 6 subjects who refused to participate in the surveys and 57 subjects for whom information on epilepsy was unavailable, 3333 subjects (71.2% of residents aged ≥40 years) were enrolled in the present study.

In the health examination, a self‐administered questionnaire was used to ask each participant whether he/she had a past history of epilepsy or was currently taking antiepileptic drugs (Appendix [S1](#epi412295-sup-0001){ref-type="supplementary-material"}). This questionnaire was checked by a trained research nurse and a pharmacist through a face‐to‐face interview. In addition, to reduce the possibility of underreporting cases of epilepsy, one of the study physicians directly asked each subject, by face‐to‐face or telephone interview, whether he/she had a history of epilepsy or any episodes of seizures in the past and whether he/she had received antiepileptic drugs. For subjects with possible epilepsy episodes or treatment, including suspected cases, the clinical records---including medical history, brain imaging, and electroencephalography reports, if available---were collected from clinics or hospitals and reviewed by a neurologist (A.T.) to determine the final diagnosis of epilepsy, the age of the first episode of seizure, and the cause of epilepsy. Epilepsy was defined as either having an episode of active epilepsy (having at least one seizure within the last 5 years)[6](#epi412295-bib-0006){ref-type="ref"} diagnosed by a local physician or a neurologist or being treated for epilepsy using antiepileptic drugs. The subjects who took antiepileptic drugs for other reasons (eg, essential tremor, neuralgia, and psychiatric disorder) were excluded from the diagnosis of epilepsy. The classification of the causes of epilepsy, the definitions of other variables, and the methods for statistical analyses are described in Appendix [S2](#epi412295-sup-0001){ref-type="supplementary-material"}.

This study was approved by the Kyushu University Institutional Review Board for Clinical Research and informed consent was obtained from all participants.

3. RESULTS {#epi412295-sec-0003}
==========

Twenty‐three subjects were diagnosed as having epilepsy, yielding an epilepsy prevalence of 6.9 per 1000 subjects with no statistically significant difference between the sexes (*P *=* *0.23; Table [1](#epi412295-tbl-0001){ref-type="table"}). The prevalence of epilepsy was significantly higher in the elderly (≥65 years; 10.3 per 1000) than in the middle‐aged (40‐64 years; 3.6 per 1000; *P *=* *0.02). The subjects who were hospitalized or institutionalized at a nursing home had a significantly higher prevalence of epilepsy (114.3 per 1000) than those living at home (3.4 per 1000; *P *\<* *0.001).

###### 

Prevalence of epilepsy, the Hisayama Study, 2012‐2013

                                                        Number of subjects with epilepsy/total subjects   Prevalence of epilepsy per 1000 (95% confidence interval)   *P*‐value between subgroups
  ----------------------------------------------------- ------------------------------------------------- ----------------------------------------------------------- -----------------------------
  All                                                   23/3333                                           6.9 (4.1‐9.7)                                               
  Age at examination, y                                                                                                                                               
  40‐64                                                 6/1679                                            3.6 (0.7‐6.4)                                               0.02
  ≥65                                                   17/1654                                           10.3 (5.4‐15.1)                                             
  Sex                                                                                                                                                                 
  Male                                                  7/1430                                            4.9 (1.3‐8.5)                                               0.23
  Female                                                16/1903                                           8.4 (4.3‐12.5)                                              
  Residence                                                                                                                                                           
  Living at home                                        11/3228                                           3.4 (1.4‐5.4)                                               \<0.001
  Hospitalized or institutionalized at a nursing home   12/105                                            114.3 (53.4‐175.1)                                          
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Among the 23 patients with epilepsy, 13 patients (57%) experienced the first episode of seizure in older age (≥65 years; Table [S1](#epi412295-sup-0001){ref-type="supplementary-material"}). The mean age at examination was significantly older and the mean value of body mass index was significantly lower in subjects with epilepsy than in those without. The subjects with epilepsy were more likely to have a history of cerebrovascular diseases and more likely to be disabled than those without epilepsy.

Except for epilepsy of unknown cause or without focal lesions, the most common cause of epilepsy in subjects overall was cerebrovascular diseases followed by congenital diseases (Figure [1](#epi412295-fig-0001){ref-type="fig"}). Among the middle‐aged subjects, the most common cause of epilepsy was congenital diseases, and among the elderly subjects it was cerebrovascular diseases.

![Causes of epilepsy among total subjects, middle‐aged subjects (aged 40‐64 years at examination), and elderly subjects (aged 65 years or older at examination) with epilepsy](EPI4-4-182-g001){#epi412295-fig-0001}

4. DISCUSSION {#epi412295-sec-0004}
=============

In this study, the prevalence of epilepsy in adults aged ≥40 years was 6.9 per 1000. A meta‐analysis of 67 prevalence studies reported that the prevalence of epilepsy worldwide irrespective of age was approximately 6.4 per 1000.[7](#epi412295-bib-0007){ref-type="ref"} A population‐based study in Tottori, Japan reported that the prevalence of epilepsy was 4.4 per 1000 in adults aged ≥20 years.[4](#epi412295-bib-0004){ref-type="ref"} A direct comparison of the prevalence of epilepsy among the studies was difficult, because the age ranges varied among the respective study populations. In general, however, the prevalence of epilepsy in the present study seemed to be similar to that in the previously reported studies. Moreover, the present study showed that the most common cause of epilepsy was cerebrovascular disease in the elderly, whereas the main cause of epilepsy was congenital diseases in the middle‐aged. The Veterans Affairs Cooperative Study from the United States also reported that cerebrovascular disease was the major cause of epilepsy in the elderly.[8](#epi412295-bib-0008){ref-type="ref"} However, to the best of our knowledge, the present study is the first to estimate the prevalence of epilepsy and its causes separately for middle‐aged and elderly subjects in a general Japanese population. The higher prevalence of epilepsy in the elderly in the present study can be explained mainly by symptomatic seizures after elderly onset cerebrovascular disease. The findings of the present study suggest the clinical importance of the prevention of cerebrovascular disease to reduce the burden of epilepsy in the future.

The present study also found that the prevalence of epilepsy in the elderly was approximately three times as high as that in the middle‐aged, and more than half of subjects with epilepsy experienced the first seizure in older age. In contrast, the above‐mentioned meta‐analysis reported that the prevalence of epilepsy in the elderly (≥ 60 years; 7.17 per 1000) was similar to that in the middle‐aged (30‐59 years; 7.94 per 1000).[7](#epi412295-bib-0007){ref-type="ref"} The exact reason for the discrepancy in these findings is unknown, but it may be attributable to a higher prevalence of epilepsy in the Japanese elderly, which in turn could be due to the longer life expectancy in Japan than in other countries.[3](#epi412295-bib-0003){ref-type="ref"} In addition, the prevalence of epilepsy in the previous reports might be underestimated as compared with our estimation, because most previous studies did not investigate hospitalized or institutionalized subjects, who have a very high prevalence of epilepsy, whereas not only subjects living at home, but also hospitalized or institutionalized subjects were surveyed in the present study.

The previous observational studies have reported disparate results regarding the sex difference in epilepsy prevalence,[9](#epi412295-bib-0009){ref-type="ref"} but a meta‐analysis did not show a clear sex difference.[7](#epi412295-bib-0007){ref-type="ref"} In the present study, the prevalence of epilepsy in women seemed to be higher than that in men but the difference did not reach the level of statistical significance. The higher prevalence in women might have been simply a matter of chance, or it might be partially explained by the older age distribution in women (mean age, 65 years) than in men (mean age, 64 years; *P *=* *0.003).

Limitations of the study should be discussed. First, there was a possibility of selection bias, since the participation rate was 71.2% among the residents aged ≥40 years. The prevalence of epilepsy might have been underestimated in the present study, because the nonparticipants could have been less healthy than the participants. However, it is generally agreed that an acceptable participation rate in a population‐based study (a rate that practically eliminates the threat of selection bias attributable to nonparticipants) is \>70% of the target population.[10](#epi412295-bib-0010){ref-type="ref"} Therefore, we believe that selection bias in the present study, if any, was modest, and thus the prevalence reported in the present study is reliable to some extent. Second, the self‐administered questionnaire was not validated and the completeness of case ascertainment was not assessed. However, we consider that the possibility of underreporting cases of epilepsy was reduced to a minimum through comprehensive screening procedures by the study team. Third, because residents aged ≤39 years were not included in the present study, a direct comparison of epilepsy prevalence with other studies was difficult. Fourth, the small sample size limited the ability to conduct detailed subgroup analyses. Fifth, we cannot deny the possibility that the cases of acute symptomatic seizure without chronic active epilepsy were misclassified into the epilepsy group, despite our detailed review of the clinical information. Sixth, because we did not collect information on epilepsy that was not currently active, lifetime prevalence of epilepsy could not be estimated.

5. CONCLUSIONS {#epi412295-sec-0005}
==============

Our study suggests that 6.9 per 1000 individuals have epilepsy in the general Japanese population, and that the prevalence of epilepsy increases with age, probably because of elderly onset cerebrovascular diseases. Intensive efforts for the prevention of cerebrovascular diseases will be needed to reduce the burden of epilepsy in the future.
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